Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.

Journal of clinical pathology - 1 Apr 2015

Kuiper Justine L, Ronden Merle I, Becker Annemarie, Heideman Daniëlle A M, van Hengel Peter, Ylstra Bauke, Thunnissen Erik, Smit Egbert F

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Carcinoma, Squamous Cell
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Fatal Outcome

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 25661795
DOI: 10.1136/jclinpath-2015-202866

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.PMID 25661795Read ↗

Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review.Semantic proximity Read ↗

Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.Semantic proximity Read ↗

Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic ImplicationsSemantic proximity Read ↗

What management for epidermal growth factor receptor-mutated non-small-cell lung cancer, with squamous cell transformation and T790M-acquired resistance mechanisms? A Case report and review of literature.Semantic proximity Read ↗

Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report.Semantic proximity Read ↗

Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition.Semantic proximity Read ↗

Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma.Semantic proximity Read ↗

Histologic transformation of epidermal growth factor receptor-mutated lung cancer.Semantic proximity Read ↗

Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitorSemantic proximity Read ↗

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.Semantic proximity Read ↗

Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.Semantic proximity Read ↗

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.